Skip to main content Skip to footer
American Family Children's Hospital
SHARE TEXT
 
David F. Jarrard, MD close
3b_ZEZIJdPU

David F. Jarrard, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Jarrard is board certified by the American Board of Urology and has completed a fellowship in Urologic Oncology. He specializes in all aspects of urologic oncology with an emphasis on prostate cancer diagnosis and treatment. Dr. Jarrard is also involved with surgical treatments for prostate cancer, such as the robotic prostatectomy.

Specialties

Clinics

University Hospital
(608) 263-4757 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 263-4757 | (800) 323-8942 | Map

Hospital Affiliation(s)

University Hospital
UnityPoint Health - Meriter
Veterans Hospital - Wm. S. Middleton Memorial

UW School of Medicine and Public Health

Department of Urology

Professional Certifications and Education

Board Certification Urology
Fellowship Urologic Oncology, The Johns Hopkins Hospital, Baltimore, MD
Residency University of Chicago Medical Center, Chicago, IL
Internship University of Chicago Medical Center, Chicago, IL
Medical School University of Virginia School of Medicine, Charlottesville, VA

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
Research

Dr. Jarrard has a joint appointment with the University of Wisconsin Carbone Cancer Center, and his clinical research emphasizes developing new therapies for genitourinary cancers. He has an active basic science laboratory and is funded through the National Institutes of Health to examine genetic and epigenetic alterations in prostate cancer.


PubMed Articles
Harshman LC Chen YH Liu G Carducci MA Jarrard D Dreicer R Hahn N Garcia JA Hussain M Shevrin D Eisenberger M Kohli M Plimack ER Cooney M Vogelzang NJ Picus J Dipaola R Sweeney CJ ECOG-ACRIN 3805 Investigators. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol . 2018 Feb 1;36(4):376-382
[PubMed ID: 29261442]
Kyriakopoulos CE Chen YH Carducci MA Liu G Jarrard DF Hahn NM Shevrin DH Dreicer R Hussain M Eisenberger M Kohli M Plimack ER Vogelzang NJ Picus J Cooney MM Garcia JA DiPaola RS Sweeney CJ Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol . 2018 Jan 31;:JCO2017753657
[PubMed ID: 29384722]
Sierra PS Damodaran S Jarrard D Clinical and pathologic factors predicting reclassification in active surveillance cohorts. Int Braz J Urol . 2018 Jan 26;44
[PubMed ID: 29368876]
Johnson BP Vitek RA Geiger PG Huang W Jarrard DF Lang JM Beebe DJ Vital ex vivo tissue labeling and pathology-guided micropunching to characterize cellular heterogeneity in the tissue microenvironment. Biotechniques . 2018 Jan 1;64(1):13-19
[PubMed ID: 29384072]
Damodaran S Damaschke N Gawdzik J Yang B Shi C Allen GO Huang W Denu J Jarrard D Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes. BMC Cancer . 2017 Dec 20;17(1):874
[PubMed ID: 29262808]
Richards KA Ruiz VL Murphy DR Downs TM Abel EJ Jarrard DF Singh H Diagnostic evaluation of patients presenting with hematuria: An electronic health record-based study. Urol Oncol . 2017 Nov 20;
[PubMed ID: 29169843]
Lee JH Yang B Lindahl AJ Damaschke N Boersma MD Huang W Corey E Jarrard DF Denu JM Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer Development. ACS Chem Biol . 2017 Nov 17;12(11):2804-2814
[PubMed ID: 28949514]
Damodaran S Kyriakopoulos CE Jarrard DF Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed? Urol Clin North Am . 2017 Nov;44(4):611-621
[PubMed ID: 29107277]
Maciolek KA Jarrard DF Abel EJ Best SL Systematic Assessment Reveals Lack of Understandability for Prostate Biopsy Online Patient Education Materials. Urology . 2017 Nov;109:101-106
[PubMed ID: 28780302]
Damaschke NA Yang B Bhusari S Avilla M Zhong W Blute ML Jr Huang W Jarrard DF Loss of <i>Igf2</i> Gene Imprinting in Murine Prostate Promotes Widespread Neoplastic Growth. Cancer Res . 2017 Oct 1;77(19):5236-5247
[PubMed ID: 28775169]
Blute ML Jr Kucherov V Rushmer TJ Damodaran S Shi F Abel EJ Jarrard DF Richards KA Messing EM Downs TM Reduced estimated glomerular filtration rate (eGFR &lt;60 mL/min/1.73 m<sup>2</sup> ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression. BJU Int . 2017 Sep;120(3):387-393
[PubMed ID: 28464520]
Wang JH Downs TM Jason Abel E Richards KA Jarrard DF Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies. Curr Urol Rep . 2017 Jul;18(7):48
[PubMed ID: 28589399]
Tazeh NN Canter DJ Damodaran S Rushmer T Richards KA Abel EJ Jarrard DF Downs TM Neutrophil to Lymphocyte Ratio (NLR) at the Time of Transurethral Resection of Bladder Tumor: A Large Retrospective Study and Analysis of Racial Differences. Bladder Cancer . 2017 Apr 27;3(2):89-94
[PubMed ID: 28516153]
Blute ML Jr Damaschke N Wagner J Yang B Gleave M Fazli L Shi F Abel EJ Downs TM Huang W Jarrard DF Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy. PLoS One . 2017;12(2):e0172048
[PubMed ID: 28234906]
Blute ML Jr Ziemlewicz TJ Lang JM Kyriakopoulos C Jarrard DF Downs TM Grimes M Shi F Mann MA Abel EJ Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. Urology . 2017 Feb;100:139-144
[PubMed ID: 27667156]
Heninger E Krueger TE Thiede SM Sperger JM Byers BL Kircher MR Kosoff D Yang B Jarrard DF McNeel DG Lang JM Inducible expression of cancer-testis antigens in human prostate cancer. Oncotarget . 2016 Dec 20;7(51):84359-84374
[PubMed ID: 27769045]
Grimes MD Blute ML Jr Wittmann TA Mann MA Zorn K Downs TM Shi F Jarrard DF Best SL Richards KA Nakada SY Abel EJ A Critical Analysis of Perioperative Outcomes in Morbidly Obese Patients Following Renal Mass Surgery. Urology . 2016 Oct;96:93-98
[PubMed ID: 27339026]
Jarrard D Konety B Huang W Downs T Kolesar J Kim KM Havighurst T Slaton J House MG Parnes HL Bailey HH Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D<sub>3</sub>) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy. Am J Clin Exp Urol . 2016;4(2):17-27
[PubMed ID: 27766277]
Blute ML Jr Zorn K Grimes M Shi F Downs TM Jarrard DF Best SL Richards K Nakada SY Abel EJ Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer. BJU Int . 2016 Sep;118(3):399-407
[PubMed ID: 26589741]
Gee JR Saltzstein DR Messing E Kim K Kolesar J Huang W Havighurst TC Harris L Wollmer BW Jarrard D House M Parnes H Bailey HH Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy. Eur J Cancer Prev . 2016 Jul;25(4):312-20
[PubMed ID: 26313229]